Ludzkie koronawirusy - autor: Krzysztof Pyrć z Zakładu Mikrobiologii, Wydział Biochemii, Biofizyki i Biotechnologii, Uniwersytet Jagielloński, Kraków

Zastanawiasz się, jak wydać pracę doktorską, habilitacyjną lub monografię? Chcesz dokonać zmian w stylistyce i interpunkcji tekstu naukowego? Nic prostszego! Zaufaj Wydawnictwu Borgis – wydawcy renomowanych książek i czasopism medycznych. Zapewniamy przede wszystkim profesjonalne wsparcie w przygotowaniu pracy, opracowanie dokumentacji oraz druk pracy doktorskiej, magisterskiej, habilitacyjnej. Dzięki nam nie będziesz musiał zajmować się projektowaniem okładki oraz typografią książki.

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - Postępy Nauk Medycznych 9/2013, s. 634-639
*Tomasz Ociepa, Emilia Sawka, Paulina Panek, Magdalena Wołczyk, Tomasz Urasiński
Ocena przydatności jednoczasowego oznaczania liczby krwinek białych i stężeń białka c-reaktywnego oraz prokalcytoniny w przewidywaniu przebiegu zakażenia u dzieci z ostrą białaczką limfoblastyczną i implantowanym centralnym cewnikiem naczyniowym
The value of concomitant measurement of white blood count, C-reactive protein and procalcitonin in predicting the course of infection in children with acute lymphoblastic leukemia and central venous catheter
Clinic of Pediatric Hematology and Oncology, Pomeranian Medical University, Szczecin
Head of Clinic: prof. Tomasz Urasiński, PhD, MD
Streszczenie
Wstęp. Zakażenia odcewnikowe odpowiadają za aż 44% wszystkich epizodów bakteremii u dzieci z ostrą białaczką limfoblastyczną (obl). Wczesna ich identyfikacja oraz odpowiednio intensywne leczenie mogą wpłynąć na poprawę wyników leczenia dziecięcej obl.
Cel. Ocena przydatności jednoczasowego oznaczania liczby krwinek białych (WBC), stężeń białka c-reaktywnego (CRP) oraz prokalcytoniny (PCT) w przewidywaniu przebiegu zakażeń u dzieci z obl.
Materiał i metody. Analizowano początkową WBC oraz stężenia CRP i PCT w przebiegu 51 epizodów gorączki u 23 dzieci z obl i implantowanym cewnikiem naczyniowym (CVC). U wszystkich pacjentów zastosowano empiryczną antybiotykoterapię.
Wyniki. Podwyższone początkowe stężenia PCT i CRP stwierdzono odpowiednio w 22/51 (43,1%) i 43/51 (84,3%) analizowanych przypadkach. Średni czas trwania gorączki, jak również średnie stężenie CRP były istotnie wyższe w przypadkach z początkową WBC poniżej 500/μl. Nie wykazano korelacji pomiędzy stężeniami CRP i PCT, jednakże średnie stężenia CRP jak również liczba dodatnich wyników posiewów krwi były istotnie wyższe w epizodach z podwyższonym początkowym stężeniem PCT. Liczba dodatnich wyników posiewów krwi była również istotnie wyższa w epizodach z jednoczasowym podwyższeniem stężeń CRP i PCT. Stwierdzono wyższe początkowe stężenia PCT ale nie CRP w epizodach z dodatnim wynikiem posiewu krwi.
Wnioski. Łączna ocena WBC oraz stężeń CRP i PCT jest przydatna w przewidywaniu przebiegu zakażeń u gorączkujących dzieci z obl i implantowanym centralnym cewnikiem naczyniowym. Umożliwia ona również wyselekcjonowanie pacjentów o wysokim ryzyku rozwoju bakteremii.
Summary
Introduction. Catheter related infections are responsible for up to 44% of episodes of bacteremia in children with acute lymphoblastic leukemia (ALL). Early prediction and intensive treatment of this complication may improve survival for children with ALL.
Aim. To assess the value of concomitant measurement of white blood count (WBC), C-reactive protein (CRP) and procalcitonin (PCT) in predicting the course of infection in children with ALL.
Material and methods. 51 febrile episodes recorded in 23 children with ALL and implanted central venous catheter (CVC) were analyzed with respect to initial WBC, CRP, PCT and CVC bacterial culture. Patients were treated with empiric antimicrobial therapy.
Results. Elevated values of PCT were found in 22/51 (43.1%) whereas values of CRP were elevated in 43/51 (84.3%) of studied episodes. Mean number of febrile days and mean CRP values were statistically higher in episodes with initial WBC less than 500/μl. There was no correlation between values of CRP and PCT however mean values of CRP and the number of episodes with positive CVC blood culture were statistically higher among those with elevated PCT. The number of positive CVC blood cultures was statistically higher in episodes where both CRP and PCT levels were elevated. There was higher initial concentration of PCT but no CRP in episodes with positive blood cultures.
Conclusion. WBC, CRP and PCT, when used together are useful indicators of the infection’s course in febrile patients with ALL and CVC. They also allow to select patients at high risk of bacteremia.
Introduction
Acute lymphoblastic leukemia (ALL) is the commonest form of childhood cancer. Now, in the advent of 21st century the majority of children with this diagnosis may enjoy long-lasting remission which in most of these patients can be considered as a cure (1). However up to 20% of children with ALL suffer from treatment failures. Most of them are relapses, but 3-15% of all children with ALL die in remission and the direct cause of their death are infections (2-4).
Central venous catheters (CVC) are routinely inserted in children with ALL allowing permanent access to venous circulation for blood sampling as well as drugs administration, blood products transfusing and parenteral nutrition. From the other site the insertion of CVC in a child with ALL is associated with a high risk of bacteremia. The rate of catheter related bacteremia in children with ALL and CVC can be as high as 44% (5, 6). It is extremely dangerous since in most of patients it occurs during profound neutropenia resulting from intensive chemotherapy. Early prediction and vigorous treatment of this complication from the very beginning may result in better outcome for children with ALL.
Two laboratory parameters: C-reacting protein (CRP) and procalcitonin (PCT) may be useful in predicting severity of infection in children with ALL. CRP is a protein produced by the liver and the adipose tissue, which enhances complement binding. It’s concentration is less than 5 mg/l in healthy individuals and rises to maximum values within 24-72 hours in response to inflammation (7). It is believed that PCT is an earlier and more specific marker of infection (8). PCT is 14-kDa prohormone of calcitonin that is synthetized by parafollicular cells of the thyroid as well as the neuroendocrine cells of the lung and the intestine. It has been shown that serum PCT levels raise in response to the presence of bacterial endotoxins in the blood; that is why PCT is considered as the marker of bacteremia in adults as well as in children (9, 10).
Aim
This study was performed in order to assess the value of concomitant measurement of white blood count, C-reactive protein and procalcitonin in predicting the course of infection in children with acute lymphoblastic leukemia and central venous catheter.
Material and methods
This retrospective study, conducted between February 1st 2007 and January 31st 2010 comprised children with ALL and implanted CVC, who developed at least one episode of fever of unknown origin that is body temperature over 38 degrees Celsius measured with the use of infrared forehead thermometer (Microlife), with no other clinical manifestation except of fever and no site of infection seen on physical examination or on imaging (e.g. chest x-ray). There were 51 episodes recorded in 23 children (12 girls and 11 boys) aged 2-14 years (mean 7.06, median 6 years).
In each of these patients blood was sampled routinely for WBC, CRP as well as PCT. PCT was measured with the use of electrochemiluminescence method (ECLIA) for quantitative determination of procalcitonin (Roche), CRP – with the use of immunoturbidimetric method for quantitative determination of C-reactive protein (Roche). Values of CRP below 5 mg/l and PCT below 0.5 ng/ml were considered normal. A sample of peripheral blood was also drawn from the catheter for bacterial cultures. These were followed by introduction of empiric antimicrobial therapy consisting of piperacillin/tazobactam (112.5 mg/kg every 8 hours) alone or in combination with amikacin (15 mg/kg once daily); the decision regarding a form of treatment was made by a physician in charge.
In patients with no clinical response to the first line antimicrobial therapy i.e. with no resolution of fever within 48 h treatment was modified: either according to the result of CVC bacterial culture or – if culture was negative – to combination of meropenem (20 mg/kg 3 times daily) plus vancomycin (20 mg/kg 3 times daily), than after subsequent 48 h – as a third step – an antifungal agent (amphotericin B or voriconazole) was added.
Duration of fever was reflected by number of days with at least one spike of body temperature over 38 degrees Celsius measured as mentioned above.
WBC, CRP and PCT values were analyzed in relation to results of central catheter blood culture (positive vs negative) and to duration of fever. The correlation between CRP and PCT values was also studied.
The normality of data was assessed with the use of Kolmogorov-Smirnov test. Statistical analysis of data was performed with the use of Fisher test, Mann-Whitney test, t-Student test and linear correlation model. Values of p < 0.05 were considered statistically significant.
Results
There were no treatment failures recorded in the group studied; in all fever episodes antimicrobial therapy resulted in resolution of fever. Mean number of febrile days as well as mean CRP values were statistically higher in episodes with initial WBC less than 500/μl (5.20 vs 10.73 days; p < 0.03, and 37.2 mg/l vs 106.8 mg/l; p < 0.005) respectively however PCT values did not differ significantly. These data are presented in table 1.
Table 1. Mean duration of fever, values of CRP and PCT in episodes with WBC ≥ 500/μl and < 500/μl.
VariableWBC ≥ 500/μl (n = 36)WBC < 500/μl (n = 15)p-value
Duration of fever (days; mean ± SD)5.2 ± 3.810.73 ± 12.5p = 0.02
PCT (ng/ml; mean ± SD)0.64 ± 0.590.76 ± 1.04p = 0.59
CRP (mg/l; mean ± SD)37.2 ± 53.13106.8 ± 97.75p = 0.0019
CVC positive blood culture7/362/15p = 0.71
OR: 1.469
95% CI: 0.75-1.69
Elevated values of PCT were found in 22/51 (43.1%) whereas values of CRP were elevated in 43/51 (84.3%) of studied episodes.
There was no correlation between values of CRP and PCT (r = 0.4983) however mean values of CRP (34.82 vs 87.78; p < 0.01) and the number of episodes with positive CVC blood culture (8/22 vs 1/29; p < 0.005) were statistically higher among those with elevated PCT. These data are presented in figure 1 and table 2.
Fig. 1. Correlation between CRP and PCT in febrile children with ALL and implanted CVC.
Table 2. Mean duration of fever, values of CRP and number of positive CVC blood culture in episodes with normal and elevated PCT concentration.
VariablePCT < 0.5 ng/ml (n = 29)PCT ≥ 0.5 ng/ml (n = 22)p-value
Duration of fever (days; mean ± SD)6 ± 4.358 ± 10.7p = 0.37
CRP (mg/l; mean ± SD)34.82 ± 46.7687 78 ± 95.51p < 0.05
CVC positive blood culture1/298/22p < 0.005
OR: 16
95% CI: 1.82-141

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.

Płatny dostęp do wszystkich zasobów Czytelni Medycznej

Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu oraz WSZYSTKICH około 7000 artykułów Czytelni, należy wprowadzić kod:

Kod (cena 30 zł za 30 dni dostępu) mogą Państwo uzyskać, przechodząc na tę stronę.
Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.

Piśmiennictwo
1. Pui CH, Campana D, Pei D et al.: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009 Jun 25; 360(26): 2730-2741.
2. Christensen MS, Heyman M, Möttönen M et al.: Nordic Society of Paediatric Haematology and Oncology (NOPHO). Treatment--related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol 2005; 131(1): 50-58.
3. Lund B, Åsberg A, Heyman M et al.: Nordic Society of Paediatric Haematology and Oncology. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer 2011 Apr; 56(4): 551-559.
4. Martinez-Albarran M, Perez-Molina Jde J, Gallegos-Castorena S et al.: Procalcitonin and C-reactive protein serum levels as markers of infection in a pediatric population with febrile neutropenia and cancer. Pediatr Hematol Oncol 2009; 26(6): 414-425.
5. Katsibardi K, Papadakis V, Charisiadou A et al.: Blood stream infections throught the entire course of acute lymphoblastic leukemia treatment. Neoplasma 2011; 58(4): 326-330.
6. Fratino G, Molinari AC, Parodi S et al.: Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Ann Oncol 2005 Apr; 16(4): 648-654.
7. Du Clos TW: Function of C-reactive protein. Ann Med 2000 May; 32(4): 274-278.
8. Andreola B, Bressan S, Callegaro S et al.: Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. Pediatr Infect Dis J 2007; 26(8): 672-677.
9. Gendrel D, Bohuon C: Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J 2000 Aug; 19(8): 679-687.
10. van Rossum AM, Wulkan RW, Oudesluys-Murphy AM: Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis 2004; 4(10): 620-630.
11. Fioretto JR, Martin JG, Kurokawa CS et al.: Interleukin-6 and procalcitonin in children with sepsis and septic shock. Cytokine 2008; 43(2): 160-164.
12. Fioretto JR, Martin JG, Kurokawa CS et al.: Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis or septic shock. Inflamm Res 2010; 59(8): 581-586.
13. Casado-Flores J, Blanco-Quirós A, Asensio J et al.: Serum procalcitonin in children with suspected sepsis: a comparison with C-reactive protein and neutrophil count. Pediatr Crit Care Med 2003; 4(2): 190-195.
14. Lodahl D, Schrøder H: Procalcitonin adds to diagnosis, but does not reduce initial antibiotics in febrile neutropenic children. Dan Med Bull 2011; 58(3): A4233.
15. Endo S, Aikawa N, Fujishima S et al.: Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study. J Infect Chemother 2008 Jun; 14(3): 244-249.
16. Dellinger RP, Levy MM, Rhodes A et al.: Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41(2): 580-637.
17. Rangel-Frausto MS, Pittet D, Costigan M et al.: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995 Jan 11; 273(2): 117-123.
18. Maruna P, Nedelníková K, Gürlich R: Physiology and genetics of procalcitonin. Physiol Res 2000; 49 (suppl. 1): 57-61.
19. Dahaba AA, Metzler H: Procalcitonin’s role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? Minerva Anestesiol 2009; 75(7-8): 447-452.
20. Kasem AJ, Bulloch B, Henry M et al.: Procalcitonin as a marker of bacteremia in children with fever and a central venous catheter presenting to the emergency department. Pediatr Emerg Care 2012; 28: 1017-1021.
21. Afzal S, Ethier MC, Dupuis LL et al.: Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J 2009; 28(12): 1064-1068.
22. Yilmaz S, Oren H, Demircio?lu F, Irken G: Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols. Pediatr Hematol Oncol 2008; 25(3): 195-204.
23. Karaman S, Vural S, Yildirmak Y et al.: Comparison of piperacillin/tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia. Pediatr Blood Cancer 2011 Jun 14. doi: 10.1002/pbc.23245. [Epub ahead of print] PubMed PMID: 21674768.
24. Zengin E, Sarper N, K?l?ç SC: Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatr Hematol Oncol 2011 May; 28(4): 311-320.
25. Erbey F, Bayram I, Yilmaz S, Tanyeli A: Meropenem monotherapy as an empirical treatment of febrile neutropenia in childhood cancer patients. Asian Pac J Cancer Prev 2010; 11(1): 123-126.
otrzymano: 2013-07-22
zaakceptowano do druku: 2013-08-26

Adres do korespondencji:
*Tomasz Ociepa
Clinic of Pediatric Hematology and Oncology Pomeranian Medical University
ul. Unii Lubelskiej 1, 71-252 Szczecin
tel.: +48 (91) 425-31-60; +48 (91) 425-31-39
e-mail: tociepa@sci.pum.edu.pl

Postępy Nauk Medycznych 9/2013
Strona internetowa czasopisma Postępy Nauk Medycznych